Obesity Adds to Racial Disparity in Early Breast Cancer
MONDAY, Dec. 7, 2020 -- For women with early breast cancer, there are considerable disparities in terms of obesity and comorbidity for Black and White women, according to a study published online Dec. 7 in Cancer.
Kirsten A. Nyrop, Ph.D., from the University of North Carolina at Chapel Hill, and colleagues conducted a retrospective chart review to examine obesity and comorbidity in Black and White women with early breast cancer (stages I to III). Data were included for 548 patients: 26 and 74 percent Black and White, respectively.
The researchers found that 62 and 32 percent of Black and White patients, respectively, were obese. Overall, 75 and 87 percent of Black and White patients, respectively, had hormone receptor-positive (HR+) tumors. There were significant differences between the groups for having two or more comorbidities (62 percent of Blacks and 47 percent of Whites); two or more obesity-related comorbidities (33 versus 10 percent); hypertension (60 versus 32 percent); diabetes mellitus (23 versus 6 percent); hypercholesterolemia or hyperlipidemia (28 versus 18 percent); and hypothyroidism (4 versus 11 percent). No intergroup differences were seen for women with HR+/human epidermal growth factor receptor 2-negative tumors regarding type of surgery, chemotherapy regimen, radiation, or endocrine treatment.
"Findings from this study need to be considered within the larger context of the cancer-obesity link and the disparate impact of the obesity epidemic on communities of color in the United States," Nyrop said in a statement.
© 2021 HealthDay. All rights reserved.
Posted: December 2020
Read this next
FRIDAY, Jan. 22, 2021 -- The incidence and prevalence of idiopathic intracranial hypertension are increasing in Wales, corresponding to increasing body mass index (BMI) in the...
FRIDAY, Jan. 22, 2021 -- There was a significant decrease in the number of patients undergoing screening tests for cancer and in the number of resulting diagnoses of cancerous and...
WEDNESDAY, Jan. 20, 2021 -- For older patients with early-stage breast cancer, a score has been developed and validated for predicting grade 3 to 5 chemotherapy toxicity,...
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.